Tennessee Code Annotated
Tenn. Code Ann. § 53-1-110 (2026)
Sale of new drugs
✓ current as of May 2026
- (a) No person shall sell, deliver, offer for sale, hold for sale or give away any new drug unless an application with respect to the drug has become effective under § 505 of the federal act.
- (b) This section shall not apply to:
- (1) A drug intended solely for investigational use by experts qualified by scientific training and experience to investigate the safety in drugs; provided, that the drug is plainly labeled "For Investigational Use Only"; and provided, further, that all reports of investigations that are being made and that have been made to show whether or not the drug is safe for use, and whether the drug is effective in use are furnished upon request to the commissioner;
- (2) A drug sold in this state at any time prior to February 15, 1941, or introduced into interstate commerce at any time prior to the enactment of the federal act; or
- (3) Any drug that is licensed under the Virus-Serum-Toxin Act (21 U.S.C. § 151 et seq.).
Acts 1941, ch. 120, § 17; C. Supp. 1950, § 6580.17; Acts 1963, ch. 226, § 2; T.C.A. (orig. ed.), § 52-117; Acts 1986, ch. 485, § 1.
Notes of Decisions
Cited in 2
cases (2 in the last 5 years), 2025–2025 · leading case: Zyla Life Sciences v. Wells Pharma, 134 F.4th 326 (5th Cir. 2025).
Zyla Life Sciences v. Wells Pharma, 134 F.4th 326 (5th Cir. 2025). “B This dispute arises between two such competitors: Zyla Life Sciences, LLC (“Zyla”) and Wells Pharma of Houston, LLC (“Wells Pharma”).”
Zyla Life Sciences v. Wells Pharma. (5th Cir. 2025). “B This dispute arises between two such competitors: Zyla Life Sciences, LLC (“Zyla”) and Wells Pharma of Houston, LLC (“Wells Pharma”).”
— Tenn. Code Ann. § 53-1-110(a) — 2 cases
Zyla Life Sciences v. Wells Pharma, 134 F.4th 326 (5th Cir. 2025). “B This dispute arises between two such competitors: Zyla Life Sciences, LLC (“Zyla”) and Wells Pharma of Houston, LLC (“Wells Pharma”).”
Zyla Life Sciences v. Wells Pharma. (5th Cir. 2025). “B This dispute arises between two such competitors: Zyla Life Sciences, LLC (“Zyla”) and Wells Pharma of Houston, LLC (“Wells Pharma”).”
Annotations are extracted automatically from the opinions in the
Syfert caselaw corpus and ranked by authority, recency, and
treatment. Dots show Syfertize treatment of the citing case itself.